Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 271

1.

Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.

Wang T, Huang Q, Reiman EM, Chen K, Li X, Li G, Lin Z, Li C, Xiao S.

J Clin Psychopharmacol. 2013 Oct;33(5):636-42. doi: 10.1097/JCP.0b013e31829a876a.

PMID:
23948786
2.

Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.

Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S.

Arch Neurol. 2009 May;66(5):632-7. doi: 10.1001/archneurol.2009.59.

3.

Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.

Yakushev I, Muller MJ, Buchholz HG, Lang U, Rossmann H, Hampel H, Schreckenberger M, Fellgiebel A.

Curr Alzheimer Res. 2012 Feb;9(2):241-7.

PMID:
22044023
4.

Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.

Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B.

Arch Neurol. 2012 Jan;69(1):29-38. doi: 10.1001/archneurol.2011.233. Epub 2011 Sep 12.

5.

Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.

Alexopoulos P, Guo LH, Jiang M, Bujo H, Grimmer T, Förster S, Drzezga A, Kurz A, Perneczky R.

J Alzheimers Dis. 2013;36(2):401-8. doi: 10.3233/JAD-122329.

PMID:
23609762
6.

CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease.

Haense C, Buerger K, Kalbe E, Drzezga A, Teipel SJ, Markiewicz P, Herholz K, Heiss WD, Hampel H.

Eur J Neurol. 2008 Nov;15(11):1155-62. doi: 10.1111/j.1468-1331.2008.02274.x. Epub 2008 Sep 18.

PMID:
18803648
7.

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.

JAMA Neurol. 2014 Oct;71(10):1282-9. doi: 10.1001/jamaneurol.2014.1358.

PMID:
25155658
8.

Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.

Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, Rich KE, Switalski R, Mehta PD, Pratico D, Zinkowski R, Blennow K, de Leon MJ.

Biol Psychiatry. 2008 Mar 15;63(6):609-18. Epub 2007 Aug 27.

9.

Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts.

Schmand B, Eikelenboom P, van Gool WA; Alzheimer's Disease Neuroimaging Initiative.

J Am Geriatr Soc. 2011 Sep;59(9):1705-10. doi: 10.1111/j.1532-5415.2011.03539.x. Epub 2011 Aug 24.

PMID:
21883100
11.

Evaluation of therapeutic response to donepezil by positron emission tomography.

Shimada A, Hashimoto H, Kawabe J, Higashiyama S, Kai T, Kataoka K, Tagawa R, Kawarada Y, Nakanishi A, Inoue K, Shiomi S, Kiriike N.

Osaka City Med J. 2011 Jun;57(1):11-9.

PMID:
22106763
12.

Longitudinal change of biomarkers in cognitive decline.

Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Oct;68(10):1257-66. doi: 10.1001/archneurol.2011.123. Epub 2011 Jun 13.

PMID:
21670386
13.

A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.

Morinaga A, Ono K, Ikeda T, Ikeda Y, Shima K, Noguchi-Shinohara M, Samuraki M, Yanase D, Yoshita M, Iwasa K, Mastunari I, Yamada M.

Dement Geriatr Cogn Disord. 2010;30(4):285-92. doi: 10.1159/000320265. Epub 2010 Sep 22.

PMID:
20861634
14.

The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.

Dowling NM, Johnson SC, Gleason CE, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2015 Jan 15;105:357-68. doi: 10.1016/j.neuroimage.2014.10.050. Epub 2014 Oct 29.

15.

Relationships between biomarkers in aging and dementia.

Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Oct 13;73(15):1193-9. doi: 10.1212/WNL.0b013e3181bc010c.

16.

Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding.

Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN.

J Nucl Med. 2009 Sep;50(9):1464-70. doi: 10.2967/jnumed.109.064360. Epub 2009 Aug 18.

17.

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A.

Brain. 2006 Nov;129(Pt 11):2856-66. Epub 2006 Jul 19.

18.

Lack of evidence for the efficacy of memantine in mild Alzheimer disease.

Schneider LS, Dagerman KS, Higgins JP, McShane R.

Arch Neurol. 2011 Aug;68(8):991-8. doi: 10.1001/archneurol.2011.69. Epub 2011 Apr 11. Review.

PMID:
21482915
19.

Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease.

Walhovd KB, Fjell AM, Brewer J, McEvoy LK, Fennema-Notestine C, Hagler DJ Jr, Jennings RG, Karow D, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

AJNR Am J Neuroradiol. 2010 Feb;31(2):347-54. doi: 10.3174/ajnr.A1809. Epub 2010 Jan 14.

20.

Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.

Förster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Förstl H, Kurz A, Grimmer T, Drzezga A.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1927-36. doi: 10.1007/s00259-012-2230-9. Epub 2012 Aug 28.

PMID:
22926714
Items per page

Supplemental Content

Write to the Help Desk